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Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in
neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their
precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients
during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy
controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF
and sVCAM-1 as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly
elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34
þ/VEGFR-2
þ) as well as their
progenitor cell population CD133
þ/CD34
þ and the population of CD34
þ stem cells increased. Concomitantly with the increase of
progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can
only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their
progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early
antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.
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Gaining access to the hosts vascular system and the maintenance
of sufficient blood supply are growth-limiting steps in tumour
progression. Most tumours form endothelial cell based vessels by
angiogenesis, the sprouting of new vessels from existing vessels,
but also an adapted form of the embryonic process of
vasculogenesis can be observed, where blood vessel are formed
de novo from endothelial precursor cells (EPC). In this process,
EPC can be mobilised from the bone marrow, transported through
the blood stream to become incorporated into the walls of growing
blood vessels (Rafii et al, 2002a; Bergers and Benjamin, 2003).
Endothelial precursor cells may reflect the phenotype of embryo-
nic angioblasts, which are migratory endothelial cells with capacity
to circulate, proliferate and differentiate into mature cells, but have
not acquired the characteristics of mature endothelium. Endothe-
lial precursor cells can be mobilised from the bone marrow and
recruited to the sites of neoangiogenesis by angiogenic growth
factors as VEGF, angiopoietin and erythropoietin (reviewed in
Rafii, 2000; Rafii et al, 2002b; Bahlmann et al, 2004; Ribatti, 2004).
The search for these EPC has shown that a subset of the
pluripotent CD34
þ stem cells has phenotypic features of
endothelial cells. The EPC were further analysed to be in the
population of CD133
þ/CD34
þ progenitor cells. In the bone
marrow, the early EPC are characterised by their expression of
CD34, CD133 and the VEGFR-2 (Flk-1, KDR) (Peichev et al, 2000).
In the circulation of adults, more mature EPC are found that have
lost CD133, but are still positive for VEGFR-2 and CD34 (Rafii,
2000; Hristov et al, 2003).
Endothelial precursor cells as well as mature endothelial cells are
detectable in the peripheral circulation (Ribatti, 2004). Mature
endothelial cells may appear in the circulation by detaching from
activated or damaged vessels. Mature endothelial cells express also
CD34 and VEGFR-2, but unlike the EPC they are negative for the
haematopoietic marker CD45 (Mancuso et al, 2001). An increase of
circulating endothelial cell (CEC) was described in several
pathologic conditions that involve vascular injury or instability
as myocardial infarction, infectious vasculitis and cancer (George
et al, 1993; Mutin et al, 1999; Mancuso et al, 2001; Beerepoot et al,
2004). These CEC are mostly viable and exhibit still proliferative
capacity despite their terminal differentiation (Lin et al, 2000;
Beerepoot et al, 2004; Ribatti, 2004).
Antiangiogenic therapy is a promising new form of cancer
treatment and the effectiveness of new angiogenesis inhibitors are
currently tested in several studies. Also for standard chemotherapy
regimen as taxanes and cyclophosphamide antiangiogenic proper-
ties are discussed (Belotti et al, 1996; Hotchkiss et al, 2002;
Lennernas et al, 2003). An antiangiogenic effect may be reflected
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sby a decrease of CEC or EPC. In this study, we quantified mature
CEC and progenitor cells in peripheral blood of breast cancer
patients undergoing anthracycline and/or taxane based neoadju-
vant treatment and subsequent surgery. The amounts of mature
CEC and progenitor cells were correlated with serum levels of
angiogenic growth factors as well as classic clinical and
pathological features of breast cancer disease.
PATIENTS AND METHODS
Patients
The study was approved by the regional ethic board of St Gallen,
Switzerland, and all patients and controls gave written informed
consent before study entry. We studied 10 female patients (for
details see Table 1) with locally advanced primary breast cancer
during the course of treatment with neoadjuvant chemotherapy
and subsequent surgery (Group A). From these patients, EDTA
and serum blood samples were withdrawn at the time of diagnosis,
after two cycles of chemotherapy, directly before surgery as well as
1 day and 4 weeks after surgery. Blood samples from age-matched
healthy females were analysed accordingly. The mean age7s.e.m.
was 49.372.6 years (range 38–61 years) for the patients and
49.272.5 years (range 37–60 years) for the controls.
Additionally, we analysed blood from 16 female patients (details
see Table 1) with primary breast cancer at the time of diagnosis
(Group B). Measurement of endothelial cells was carried out within
24h after venous puncture. For the serum samples, blood was
withdrawn in additive-free vacutainers (BD Vacutainer Systems,
Basel, Switzerland) and allowed to clot for 30min at room
temperature. Then the samples were centrifuged at 2700g for
10min, and the serum was aliquoted and stored at  801C until
ELISA measurement.
The amount of endothelial cells and the concentration of serum
factors were correlated with the clinical tumour stage and the
following pathological features (TNM classification; Greene et al,
2002): pathological tumour size (pT, ypT respectively; y stands for
histological assessment after antineoplastic therapy), nodal status
(pN, ypN respectively), tumour grading, oestrogen receptor status,
progesterone receptor status and regression grade after Sinn et al
(1994). Immunohistochemical expression of HER-2/neu was
evaluated according to the published scoring guidelines of the
HercepTest (Dako, Zug, Switzerland). Patients were subgrouped
according to their immunohistochemistry (IHC) score and the
result of the fluorescence in situ hybridisation into a FISH positive
or IHC score 3þ group vs a FISH negative or IHC score 1þ group.
Measurement of angiogenic factors
Serum levels of growth factors were quantified by sandwich ELISA.
FGF basic, VEGF and sVCAM-1 were measured using DuoSet
ELISA Kits from R&D Systems (Wiesbaden, Germany), according
to the manufacturer’s instructions with minor modifications: For
sVCAM-1, the capture antibody was used with 0.5mgml
 1 and the
tracer with 72ngml
 1, the highest standard was 5000pgml
 1.
Table 1 Characterisation of patients analysed in this study
Patient
Age
(years) cT ER (+/ ) PR (+/ )
HER2
(+/ )
Tumour
grading Therapy
Regression
grade after Sinn
(A) Patients Group A
13 8 3 +   ND ND ET (6 cycles) 3
24 0 2    + 3 CEF (6 cycles) 1
35 2 3    + 3 CEF (4 cycles), trastuzumab/paclitaxel (6 cycles) 4
46 1 2    + 3 ET (5 cycles) 0
55 6 2 + +   2 FEC (6 cycles) 1
65 4 3 + +   3 CEF (5 cycles) 1
74 8 4 + +   2 CEF (6 cycles) 2
84 2 4    + 3 CEF (5 cycles), trastuzumab/paclitaxel (4 cycles) 0
9 43 4 + + + 3 ET (6 cycles) 3
10 59 2 + +   3 CEF (5 cycles) 1
(B) Patients Group B
13 7 2     3
25 5 1 + +   2
36 9 1 + +   1
46 0 1 + + + 1
55 4 1 + +   1
66 6 2 + + N D 3
7 69 1 + + ND NA
(pT¼1mm)
84 4 1 + +   2
96 1 1    +3
10 67 Tis
(DCIS)
+ + ND NA
11 67 2 + + + 2
12 39 3 + +   2
13 41 3 + + + 2
14 71 3    ND 3
15 39 2 + +   3
16 61 2 + +   1
Group A: Blood samples of these patients were analysed during the course of neoadjuvant chemotherapy and subsequent surgery. (B) Group B: Blood samples of these patients
were analysed at the time of diagnosis. cT: primary tumour size; ER: oestrogen receptor expression; PR: progesterone receptor expression; HER2: overexpression of HER-2/neu;
ET: epirubicin/docetaxel; CEF: cyclophosphamide/epirubicin/5-fluorouracil; FEC: 5-fluorouracil/epirubicin/cyclophosphamide; ND: not determined; NA: not applicable, pT:
pathological tumour size.
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sSoluble endoglin (sCD105), erythropoietin, angiopoietin-2, and
endostatin were measured using Quantikine ELISA kit (R&D
Systems) according to the manufacturer’s instructions.
Flow cytometry
For measurement of CECs and progenitor cells, a method from
Mancuso et al (2001) was adapted. Flow cytometric analysis was
carried out in whole blood without any enrichment procedure to
avoid enrichment artefacts. Mature CEC were defined as negative
for haematopoietic marker CD45 and positive for endothelial
markers CD146 (P1H12), CD31 and CD34. Activated CEC were
defined as CD45
 , CD34
þ, CD105
þ or CD106
þ. Endothelial
precursor cells were defined as CD34
þ, CD45
low and VEGFR-2
þ.
For the flow cytometric analysis, 100ml EDTA blood was stained
with one of the following antibody panels: (A) 5ml anti-CD31-FITC
(clone WM59, Serotec), 1ml P1H12-PE (clone P1H12, Chemicon),
5ml anti-CD45-PerCP (clone 2D1, BD Biosciences, Allschwil,
Switzerland) and 5ml anti-CD34-APC (clone 8G12, BD Bio-
sciences). (B) 5ml anti-CD31-FITC, 5ml anti-CD133-PE (clone
AC133, Miltenyi Biotec, Bergisch Gladbach, Germany), 5ml anti-
CD45-PerCP and 5ml anti-CD34-APC. (C) 5ml anti-CD106-FITC
(clone 1.G11B1, Serotec), 5ml anti-CD105-PE (clone SN6, Serotec),
5ml anti-CD45-PerCP and 5ml anti-CD34-APC. (D) 20ml anti-KDR-
Biotin (goat IgG, R&D Systems, Wiesbaden, Germany), 5ml anti-
CD133-PE, 5ml anti-CD45-PerCP and 5ml anti-CD34-APC and after
washing with PBS in a second staining step 1ml Streptavidin-FITC
(Dako) was added to the blood and incubated for 15min at room
temperature. For quantification of CECs and progenitor cells,
a known amount of 6mm latex microspheres (Polyscienes,
Eppelheim, Germany) was added to the blood as an internal
standard. After incubation for 30min at room temperature, 1ml BD
Lysing Solution (Becton Dickinson) was added to lyse erythrocytes
and fixate cells. After 10min, cells were washed twice with 1ml PBS
and measured in a FACS LSR flow cytometer (BD Biosciences)
using Cell Quest software (BD Biosciences). In each blood sample,
300000 events were counted. Gating details are given in the
supplementary online material (Supplementary Figure 1).
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Figure 1 Flow cytometric quantification of CEC. The amounts of CEC were quantified in peripheral blood samples of breast cancer patients and matched
controls by four colour flow cytometry analysis. (A) Comparison of CEC amounts in blood samples from patients (group A) at the time of diagnosis and
matched controls. **Po0.01 vs matched controls. (B) CEC levels during the course of neoadjuvant chemotherapy and subsequent surgery. *Po0.05,
**Po0.01 vs values at time of diagnosis. (C) Comparison of CEC amounts in blood samples from breast cancer patients (Groups AþB) with oestrogen
receptor negative and oestrogen receptor positive tumours at the time of diagnosis. *Po0.05 vs values of oestrogen receptor negative patients. (D)
Comparison of CEC amounts in blood samples from breast cancer patients (Groups AþB) with progesterone receptor negative and progesterone
receptor positive tumours at the time of diagnosis. P¼0.067 vs values of progesterone receptor negative patients.
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sStatistical analysis
Statistical analysis was performed using GraphPad Instat (Instat
Statistics, GraphPad Software). For all data parametric testing was
performed. For the comparison of the subsequent blood with-
drawals from the same patients paired testing with a paired t-test
was performed. For the comparison of patients and controls or
patient subgroups, an unpaired t-test was used. Differences were
considered statistically significant at Po0.05.
RESULTS
Quantification of CEC
The flow cytometric quantification of mature CEC showed
significantly (Po0.01) elevated amounts of CEC in the patient
samples (median: 5.7CECml
 1 blood) at the time of diagnosis
compared to the matched controls (median: 1.3CECml
 1 blood)
(Figure 1A). The analysis of CEC during the course of treatment
showed that CEC were reduced under neoadjuvant treatment
compared to pretreatment values (Figure 1B). This reduction was
significant (Po0.05 and o0.01 respectively) in the blood samples
taken before and one day after surgery. There was no direct
correlation of CEC amounts with the concentration of the
measured serum factors, including VEGF and sVCAM-1. The
comparison of CEC levels with clinico-pathological data showed
that the amounts of CEC did not differ between patients
categorised into four clinical tumour stage (cT) groups. There
was also no difference in the amounts of CEC when patients were
subgrouped according to their tumour grading or Her2 receptor
status. The classification according to the hormone receptor status
showed significantly (P¼0.025) increased CEC amounts in
oestrogen receptor negative patients compared to receptor positive
patients (Figure 1C). The progesterone receptor negative patients
showed also increased CEC amounts when compared to the
receptor positive patients, but this increase was not significant
(P¼0.067) (Figure 1D). Further, there was no correlation between
the extent of CEC reduction during chemotherapy and the
observed pathological tumour regression grade according to Sinn.
Clinically, nine patients achieved a partial response. The clinical
response of one patient was assessed as stable disease.
For the activated endothelial cells characterised by the expres-
sion of CD105 or CD106, we found no difference between patients
and controls and also no changes during the course of anticancer
treatment.
Quantification of progenitor cells
For the quantification of progenitor cells, we analysed the total
population of CD34
þ cells, which are the general haematopoietic
stem cells, and the subpopulation of CD133
þ/CD34
þ cells, the
progenitor population that also contains the EPC. Early EPC
characterised by the expression of CD34, CD133 and the VEGFR-2
(Flk-1, KDR) are present in the circulation at very low numbers
and cannot be quantified by flow cytometry without previous
enrichment procedure. But the more mature EPC, which are
positive for CD34 and the VEGFR-2, could be measured in the
blood samples. The amount of CD34
þ cells was 2.2cellsml
 1 blood
(median) for the patients and 0.8cellsml
 1 blood (median) for
the controls (Figure 2A). This difference was not significant
(P¼0.094). The patients also displayed higher amounts of
CD133
þ/CD34
þ cells (median: 0.8cellsml
 1 blood) when com-
pared to the healthy controls (median: 0.4cellsml
 1 blood), but
this difference was not significant (Figure 2A). The amounts of
CD34
þ cells and CD133
þ/CD34
þ cells were both significantly
(Po0.05) increased after two cycles of chemotherapy compared to
pretreatment values and these elevated levels normalised thereafter
(Figure 2B and C).
Patients with clinical tumour stage (cT) 1 had significantly
(Po0.05) higher amounts of CD34
þ cells compared to patients
with clinical tumour stage 3 or 4 (Figure 2D). This trend was also
observed for the CD133
þ/CD34
þ cells, but was not significant
(Po0.1) (Figure 2E). There was no difference in the amounts of
CD34
þ cells and CD133
þ/CD34
þ cells when patients were
subgrouped according to their tumour grading, hormone receptor
status or Her2 receptor status.
The amount of circulating EPC (CD34
þ/VEGFR-2
þ) was
0.37cellsml
 1 blood (median) for the patients at the time of
diagnosis and 0.14cellsml
 1 blood (median) for the matched
controls (Figure 3A). This difference was not significant (P¼0.09).
After two cycles of chemotherapy, the amount of circulating EPC
increased to 0.68EPCml
 1 blood (median). A closer analysis of this
increase showed that in 50% of the patients EPC levels increased,
whereas in the other half EPC amounts slightly decreased. The
patients, who reacted to chemotherapy with an increase in EPC
numbers, had low EPC amounts before treatment (median:
0.17EPCml
 1 blood) and their EPC counts increased after two
cycles of chemotherapy to 0.97EPCml
 1 blood (median). The
nonresponding patients already had 0.66EPCml
 1 blood (median)
before treatment and EPC levels slightly decreased to 0.5EPCml
 1
blood (median) after chemotherapy. After two cycles of chemo-
therapy and before surgery, the amount of EPC was significantly
increased (P¼0.011 and 0.033 respectively) in comparison to the
matched controls (Figure 3B).
Measurement of angiogenesis-relevant serum factors
The concentration of serum factors that influence angiogenesis
were determined by ELISA. The serum concentration of FGF basic
was below the detection limit of the ELISA. For sVCAM-1 we found
significantly (Po0.05) elevated levels in patients (median:
394ngml
 1) compared to the controls (median: 253ngml
 1).
Serum levels of VEGF were higher in patients (median:
138pgml
 1) than in controls (median: 92pgml
 1), but this
difference was not significant (P¼0.1). The concentrations of
erythropoietin, angiopoietin-2 and soluble endoglin did not differ
significantly between patients and controls.
Oestrogen receptor positive patients showed elevated levels of
endostatin (median: 121ngml
 1) compared to oestrogen receptor
negative patients (median: 104ngml
 1). This difference was not
significant (P¼0.057). Also progesterone positive patients showed
significantly (P¼0.03) elevated levels of endostatin (median:
122ngml
 1) compared to progesterone receptor negative patients
(median: 103ngml
 1). Concomitantly with the increase of CD34
þ
cells and CD133
þ/CD34
þ cells, a significant increase of VEGF
(Po0.05), erythropoietin (Po0.01) and angiopoietin-2 (Po0.05)
and a significant decrease of soluble endoglin (Po0.01) were
observed after two cycles of chemotherapy compared to pre-
therapeutic values (Table 2). The increase in the levels of VEGF,
erythropoietin and angiopoietin-2 was followed by an increase of
endostatin before surgery (Po0.01, Table 2). Erythropoietin
remained elevated throughout the chemotherapy period, whereas
angiopoietin-2 and VEGF returned to basal levels. Soluble endoglin
remained decreased during the course of treatment.
DISCUSSION
In the presented study we investigated the changes of mature CEC,
EPC, their progenitor cells and angiogenesis-relevant growth
factors during the course of anthracycline and/or taxane based
chemotherapy and subsequent surgery. We could demonstrate that
CEC levels are increased 4.4 times in primary breast cancer
patients compared to matched healthy controls. This is consistent
with previous findings where increased levels of CEC were
described in patients with various cancer types in comparison to
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sFigure 2 Flow cytometric quantification of CD34
þ and CD34
þ/CD133
þ progenitor cells. The amounts of CD34
þ and CD34
þ/CD133
þ progenitor
cells were quantified in peripheral blood samples of breast cancer patients and matched controls by four colour flow cytometry analysis. (A) Comparison of
the amounts of CD34
þ and CD34
þ/CD133
þ progenitor cells in blood samples from patients (Group A) at the time of diagnosis and matched controls.
P¼0.094 vs values of matched controls. (B) CD34
þ levels during the course of neoadjuvant chemotherapy and subsequent surgery. *Po0.05 vs values at
time of diagnosis. (C) CD34
þ/CD133
þ levels during the course of neoadjuvant chemotherapy and subsequent surgery. *Po0.05 vs values at time of
diagnosis. (D) Comparison of CD34
þ amounts in blood samples from breast cancer patients (Groups AþB) with different clinical tumour stages at the
time of diagnosis. *Po0.05 vs values of patients with clinical tumour stage 1. (E) Comparison of CD34
þ/CD133
þ amounts in blood samples from breast
cancer patients (Groups AþB) with different clinical tumour stages at the time of diagnosis.
CEC during chemotherapy
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shealthy controls (Mancuso et al, 2001; Beerepoot et al, 2004). We
could further show that these elevated CEC levels decrease
significantly after anthracycline/taxane based chemotherapy, but
CEC levels did not reach the level of the healthy controls.
In a previous study it was described that plasma levels of
sVCAM-1 and VEGF correlated with the amounts of CEC
(Mancuso et al, 2001). We observed increased serum levels of
sVCAM-1 and VEGF in patients compared to the matched
controls, but we did not detect a direct correlation between any
growth factor and the amounts of CEC. Since mature CEC are
probably detached cells from activated or damaged vessels, their
number could reflect the extent of tumour neovasculature. This is
supported by the findings that in cancer patients elevated numbers
of CEC are detected and that the CEC counts normalise when the
tumour is removed by surgery or chemotherapy (Mancuso et al,
2001; Beerepoot et al, 2004). The number of CEC in tumour
patients could be influenced by many factors as the localisation of
the tumour and the extent of the tumour vasculature, the
activation and proliferation status of the endothelial cells in the
tumour area and also the activation of matrix metalloproteases
that could facilitate the detachment of endothelial cells. Thus, it is
not surprising that no direct correlation between a single growth
factor and the CEC numbers was detected. Further, the number of
CEC was not associated with clinical tumour grading or tumour
size. This could again be explained by the complexity of factors
that could influence the amounts of CEC.
In our small study, CEC levels at the time of diagnosis were
significantly lower in oestrogen-receptor positive breast cancer
patients compared to receptor negative patients. In parallel,
oestrogen receptor positive patients showed elevated levels of
endostatin. This was similarly true for progesterone positive
patients (lowered CEC levels and elevated endostatin levels).
Endostatin, an inhibitor of angiogenesis and tumour growth, is a
fragment of the NC1 domain of collagen XVIII. It can be generated
via proteolytic cleavage of collagen XVIII by cathepsin L or various
other proteases (Felbor et al, 2000; Ferreras et al, 2000). An
association of CEC numbers and endostatin levels with hormone-
receptor status has not been described before and should be
further analysed in studies with high patient numbers. This link
could be part of the explanation for the better prognosis of
hormone-receptor positive breast cancer. This aspect gains
support by an observation that breast cancer patients with elevated
endostatin levels following surgery showed a lower risk of relapse
(Zhao et al, 2004). Further, a recent publication showed that
endostatin dramatically inhibits endothelial cell migration, vas-
cular morphogenesis and perivascular cell recruitment in vivo
(Skovseth et al, 2005). These findings underscore the impact of
endostatin on endothelial cells in vivo and sustain the hypothesis
of a direct relationship between lowered CEC levels and elevated
serum endostatin. We also observed a tendency to decreased
angiopoietin-2 levels in hormone receptor positive patients
underlining a relative antiangiogenic status in hormone-receptor
positive breast cancer patients. A possible link between endostatin
and oestrogen receptors could be the oestrogen-dependent
regulation of proteases, for example, the induction of transcription
of the lysosomal aspartyl protease cathepsin D by oestrogens
(Cavailles et al, 1993). Thus, in oestrogen-receptor positive
tumours, such proteases could be expressed leading to increased
proteolytic release of endostatin.
Figure 3 Flow cytometric quantification of EPC (CD34
þ/VEGFR-2
þ).
The amounts of EPC were quantified in peripheral blood samples of breast
cancer patients and matched controls by four colour flow cytometry
analysis. (A) Comparison of the amounts of EPC in blood samples from
patients at the time of diagnosis and matched controls. P¼0.09 vs values of
matched controls. (B) EPC levels during the course of neoadjuvant
chemotherapy and subsequent surgery. *Po0.05 vs values of matched
controls.
Table 2 Measurement of serum VEGF, erythropoietin, angiopoietin-2, soluble endoglin and endostatin
At diagnosis After 2 cycles chemotherapy Before surgery 1 day after surgery 4 weeks after surgery
VEGF (pgml
 1) 138 (106/170) 167* (99/257) 147 (106/230) 161 (116/199) 164 (104/274)
Erythropoietin (mIUml
 1) 14.5 (9.9/17.9) 23.4* (16.4/31.6) 20.3** (12.8/27) 38.8* (25.1/53.4) 23.9*** (21.4/28.7)
Angiopoietin-2 (pgml
 1) 2317 (1682/2651) 2935* (1874/3309) 2280 (1874/3309) 2474 (2012/2760) 2370 (2169/2656)
Endoglin (ngml
 1) 4.4 (4.1/5) 4.2** (3.8/4.5) 4.3 P¼0.066 (4/4.6) 3.7*** (3.4/4) 4.3 (4.1/5)
Endostatin (ngml
 1) 109 (98/119) 119 (91/141) 122* (112/144) 110 (97/124) 119 (113/127)
The concentrations of VEGF, erythropoietin, angiopoietin-2, soluble endoglin and endostatin were quantified by ELISA in serum samples of breast cancer patients during the
course of neoadjuvant chemotherapy and subsequent surgery. In the table, median values (25% percentile/75% percentile) are given. *Po0.05, **Po0.01, ***Po0.001 vs values
at time of diagnosis.
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sBesides the impact of chemotherapy on CEC levels, we were also
interested in the influence of this treatment on the amounts of EPC
and their progenitor cells. Our results demonstrated that in the
initial phase of chemotherapy, a general mobilisation of progenitor
cells was induced. This is a well-known phenomenon observed
during various chemotherapy regimens (Schwartzberg et al, 1992).
The induction was marked on a cellular level by elevated amounts
of CD34
þ stem cells, CD34
þ/CD133
þ progenitor cells and
circulating EPC and was accompanied by increased levels of
VEGF, angiopoietin-2 and erythropoietin. Of the multitude of
growth factors that regulate physiological and pathological
angiogenesis, VEGF is believed to be the most important. VEGF
is a potent mitogen for vascular endothelial cells and it is also
essential for the mobilisation of bone-marrow-derived endothelial
precursors (Asahara et al, 1999a). Concurrently, erythropoietin
is not only mobilising the CD34
þ stem cells, it also increases the
number of functionally active EPC as it was shown in humans after
administration of recombinant erythropoietin (Bahlmann et al,
2004). In tumour patients with relative high amounts of EPC,
chemotherapy did not induce a further increase in this population,
whereas in patients with low EPC numbers chemotherapy induced
a 5.7-fold increase in circulating EPC amounts. The increased
amounts of EPC, the mobilisation of the progenitor pool from
which the EPC originate and increased proangiogenic serum
factors reflect an increased angiogenic potential induced by
chemotherapy. This first observation from our small study raises
the question if this initial proangiogenic state is of clinical
relevance in cancer disease and should be covered by a
concomitant antiangiogenic therapy. This question seems parti-
cularly important regarding the vessel-forming potential of EPC:
EPC have a high proliferative and regenerative potential, they can
home to sites of neoangiogenesis and differentiate into mature EC
in response to angiogenic growth factors (Asahara et al, 1997,
1999b; Takahashi et al, 1999; Kalka et al, 2000; Lin et al, 2000;
Murohara et al, 2000). Bone marrow derived haemangiopoetic
progenitor cells can fully support tumour growth (Peichev et al,
2000) and contribute to tumour neovasculature (Davidoff et al,
2001), as demonstrated in bone marrow transplant models. Based
on these aspects, an increase in EPC or the progenitor cells that
could differentiate into EPC may pose a risk for the patients since
these cells could contribute to tumour neovascularisation and thus
could increase the risk of relapse. Therefore, it seems worthwhile
to design clinical trials combining chemotherapy with emerging
antiangiogenic drugs to explore the impact of the initial
prohaemangiogenic status induced by chemotherapy.
In conclusion, we could show that both mature CEC and EPC are
influenced by chemotherapy: CEC numbers declined during
chemotherapy, whereas EPC and their progenitor pool were
mobilised. For the assessment of the angiogenic status and for
evaluation of the effectiveness of antiangiogenic therapies, it is
important to consider both populations (together with relevant
angiogenic serum factors), since both of these populations could
contribute to neovascularisation.
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